keyword
MENU ▼
Read by QxMD icon Read
search

Oligometastatic

keyword
https://www.readbyqxmd.com/read/28434661/retrospective-review-of-percutaneous-image-guided-ablation-of-oligometastatic-prostate-cancer-a-single-institution-experience
#1
Andrew J Erie, Jonathan M Morris, Brian T Welch, A Nicholas Kurup, Adam J Weisbrod, Thomas D Atwell, Grant D Schmit, Eugene D Kwon, Matthew R Callstrom
PURPOSE: To retrospectively review and report the efficacy and safety of percutaneous image-guided ablation (cryoablation or radiofrequency ablation) in the treatment of oligometastatic prostate cancer. MATERIALS AND METHODS: An institutional registry was retrospectively reviewed and revealed 16 patients with oligometastatic prostate cancer (median age, 67 y; range, 50-86 y) who underwent percutaneous image-guided ablation to treat 18 metastatic sites. A subgroup of 7 patients with 8 metastases were androgen-deprivation therapy (ADT)-naïve and underwent ablation to delay initiation of ADT...
April 20, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28433508/organs-at-risk-in-lung-sbrt
#2
REVIEW
F De Rose, D Franceschini, G Reggiori, A Stravato, P Navarria, A M Ascolese, S Tomatis, P Mancosu, M Scorsetti
Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high 'ablative' doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications...
April 19, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28431712/salvage-operation-in-case-of-oligometastatic-disease
#3
Nicolas Duchateau, Erik Van Bouwel, Paul E Van Schil
In general, prognosis of stage IV non-small cell lung cancer is poor, and treatment is mostly palliative. However, oligometastatic disease is currently recognized as a specific entity with a better prognosis. We report a patient where combined chemoradiotherapy and salvage surgery led to extraordinary long-term survival.
May 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28401364/ablative-therapies-in-metastatic-breast-cancer-a-systematic-review
#4
REVIEW
Michael Jonathan Kucharczyk, Sameer Parpia, Cindy Walker-Dilks, Laura Banfield, Anand Swaminath
PURPOSE: Patients with oligometastatic breast cancer are being increasingly offered ablative therapies, yet it is unclear which subpopulations may derive long-term benefit. This study sought to explore factors that could define a clinically relevant oligometastatic breast cancer population that benefits from ablative therapies. METHODS: A systematic review using MEDLINE for English language articles published between 1985 and April 2014 was undertaken. Criteria for review included studies that reported overall survival (OS) or progression-free survival (PFS) in breast cancer patients with distant metastases which also: quantified the extent of disease, had metachronous presentation of metastases, and reported on at least 5 patients...
April 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28384678/metastasectomy-for-abdominal-visceral-oligometastatic-melanoma
#5
Danielle K DePeralta, Jonathan S Zager
No abstract text is available yet for this article.
April 5, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/28377206/ablative-therapy-for-oligometastatic-non-small-cell-lung-cancer
#6
REVIEW
Oscar Juan, Sanjay Popat
The oligometastatic state represents a distinct entity among those with metastatic disease and consists of patients with metastases limited in number and location, representing an intermediate state between locally confined and widely metastatic cancer. Although similar, "oligorecurrence" (limited number of metachronous metastases under conditions of a controlled primary lesion) and "oligoprogressive" (disease progression at a limited number of sites with disease controlled at other disease sites) states are distinct entities...
March 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28363660/expanding-role-of-percutaneous-ablative-and-consolidative-treatments-for-musculoskeletal-tumours
#7
REVIEW
A N Kurup, M R Callstrom
Interventional approaches to musculoskeletal tumours have significantly changed over the last several years, and new treatments continue to be developed. All ablative modalities are currently applied to the treatment of bone tumours, including radiofrequency, cryo-, microwave, and laser ablation devices. Indications for ablation of bone and soft-tissue tumours have expanded beyond palliation of painful bone metastases and eradication of osteoid osteomas to the local control of oligometastatic disease from a number of primary tumours and ablation of desmoid tumours...
March 28, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28361073/is-there-a-benefit-to-locally-consolidative-therapy-for-oligometastatic-non-small-cell-lung-cancer
#8
EDITORIAL
Lauren Boreta, Sue S Yom
No abstract text is available yet for this article.
March 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28359734/complications-after-metastasectomy-for-renal-cell-carcinoma-a-population-based-assessment
#9
Christian P Meyer, Maxine Sun, Jose A Karam, Jeffrey J Leow, Guillermo de Velasco, Sumanta K Pal, Steven L Chang, Quoc-Dien Trinh, Toni K Choueiri
Metastasectomy has long been considered a valid treatment option for patients with oligometastatic renal cell carcinoma (oligo-mRCC). However, the literature on complications in this setting is scarce. Our objective was to describe in-hospital complications after metastasectomy in a contemporary cohort of patients with mRCC. Using the National Inpatient Sample database (2000-2011), 45 279 mRCC patients were identified. Of those, 1102 underwent metastasectomies. The metastatic sites were the lungs, bone, liver, lymph nodes, adrenal glands, and brain in, respectively, 52%, 29%, 19%, 14%, 11%, and 3...
March 27, 2017: European Urology
https://www.readbyqxmd.com/read/28343352/the-role-of-hypofractionated-radiotherapy-in-prostate-cancer
#10
REVIEW
Linus C Benjamin, Alison C Tree, David P Dearnaley
PURPOSE OF REVIEW: It is now accepted that prostate cancer has a low alpha/beta ratio, establishing a strong basis for hypofractionation of prostate radiotherapy. This review focuses on the rationale for hypofractionation and presents the evidence base for establishing moderate hypofractionation for localised disease as the new standard of care. The emerging evidence for extreme hypofractionation in managing localized and oligometastatic prostate cancer is reviewed. RECENT FINDINGS: The 5-year efficacy and toxicity outcomes from four phase III studies have been published within the last 12 months...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28325637/long-term-control-of-oligometastatic-prostate-cancer-after-stereotactic-body-radiotherapy-in-the-absence-of-androgen-deprivation-therapy-a%C3%A2-case-report
#11
Mark C Markowski, Philip Imus, Jean L Wright, Douglas Schottenstein, Channing J Paller
No abstract text is available yet for this article.
February 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28314971/-when-is-surgical-treatment-indicated-in-metastatic-prostate-cancer-and-what-is-the-scientific-rationale
#12
A Kretschmer, A Herlemann, C G Stief, C Gratzke
BACKGROUND: Recent improvements in imaging diagnostics has led to a rising incidence of oligometastatic prostate cancer and, most notably, an increasing incidence of nodal-only biochemical recurrences. In this clinical setting, systemic therapy is still the treatment of choice. However, there is increasing evidence for surgical approaches in this challenging clinical setting. AIM OF THE STUDY: In this comprehensive review article, current evidence regarding surgical approaches of primary nodal metastases, nodal-only biochemical recurrence following radical prostatectomy, and osseous metastatic prostate cancer will be discussed...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28297304/evaluation-of-kidney-motion-and-target-localization-in-abdominal-sbrt-patients
#13
Marcus Sonier, William Chu, Nafisha Lalani, Darby Erler, Patrick Cheung, Renee Korol
The purpose of this study was to evaluate bilateral kidney and target translational/rotational intrafraction motion during stereotactic body radiation therapy treatment delivery of primary renal cell carcinoma and oligometastatic adrenal lesions for patients immobilized in the Elekta BodyFIX system. Bilateral kidney motion was assessed at midplane for 30 patients immobilized in a full-body dual-vacuum-cushion system with two patients immobilized via abdominal compression. Intrafraction motion was assessed for 15 patients using kilovoltage cone-beam computed tomography (kV-CBCT) datasets (n=151) correlated to the planning CT...
November 2016: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28296712/association-between-the-use-of-surveillance-pet-ct-and-the-detection-of-potentially-salvageable-occult-recurrences-among-patients-with-resected-high-risk-melanoma
#14
Roberto A Leon-Ferre, Lisa A Kottschade, Matthew S Block, Robert R McWilliams, Roxana S Dronca, Edward T Creagan, Jacob B Allred, Val J Lowe, Svetomir N Markovic
The optimal surveillance for patients with resected high-risk melanoma is controversial. Select locoregional or oligometastatic recurrences can be cured with salvage resection. Data on the ability of PET/CT to detect such recurrences are sparse. We evaluated whether surveillance PET/CT in patients with resected stage III-IV melanoma led to detection of clinically occult recurrences amenable to curative-intent salvage treatment. We retrospectively identified 1429 melanoma patients who underwent PET/CT between January 2008 and October 2012 at Mayo Clinic (Rochester, Minnesota)...
March 14, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28293485/a-long-term-survivor-of-metastatic-pancreatic-adenocarcinoma-free-of-recurrence-12-years-after-treatment-of-oligometastatic-disease
#15
John M Stahl, Zenta Walther, Bryan W Chang, Howard S Hochster, Kimberly L Johung
Aggressive local therapy for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC) has traditionally not been pursued due to high rates of distant progression. We describe a 62-year-old male initially presenting with resectable PDAC who underwent the Whipple procedure but developed multiple liver metastases within two months of starting adjuvant gemcitabine. Oxaliplatin was added to the regimen and complete resolution of the liver lesions resulted. He remained disease-free for five years until re-staging revealed a small lung nodule...
February 2, 2017: Curēus
https://www.readbyqxmd.com/read/28283344/-gotta-catch-em-all-or-do-we-pokemet-approach-to-metastatic-prostate-cancer
#16
EDITORIAL
Declan G Murphy, Christopher J Sweeney, Bertrand Tombal
Metastasis-directed therapy is of interest for the management of oligometastatic prostate cancer. Improved imaging may help with patient selection, but the approach to metastatic prostate cancer of "catching 'em all", or "Pokemet", must be considered experimental.
March 7, 2017: European Urology
https://www.readbyqxmd.com/read/28275501/who-are-appropriate-surgical-candidates-among-patients-with-oligometastatic-non-small-cell-lung-cancer
#17
COMMENT
Tomoyuki Hishida
No abstract text is available yet for this article.
February 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28275479/should-aggressive-thoracic-therapy-be-performed-in-patients-with-synchronous-oligometastatic-non-small-cell-lung-cancer-a-meta-analysis
#18
Dianhe Li, Xiaoxia Zhu, Haofei Wang, Min Qiu, Na Li
BACKGROUND: We performed a meta-analysis to compare overall survival (OS) outcomes in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) who underwent aggressive thoracic therapy (ATT) with those who did not. METHODS: A systematic review of controlled trials of ATT on survival in synchronous oligometastatic NSCLC was conducted. Hazard ratio (HR) for the main endpoint OS was pooled using a fixed-effects model. Subgroup analysis was performed in patients with single organ metastases, or with different numbers of brain metastases, or with different stages of thoracic disease...
February 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28274491/stereotactic-body-radiotherapy-for-oligo-metastatic-liver-disease-influence-of-pre-treatment-chemotherapy-and-histology-on-local-tumor-control
#19
R J Klement, M Guckenberger, H Alheid, M Allgäuer, G Becker, O Blanck, J Boda-Heggemann, T Brunner, M Duma, S Gerum, D Habermehl, G Hildebrandt, V Lewitzki, C Ostheimer, A Papachristofilou, C Petersen, T Schneider, R Semrau, S Wachter, N Andratschke
INTRODUCTION: Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology. METHODS: 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database...
March 5, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28266145/safety-and-efficacy-of-microwave-ablation-for-medically-inoperable-colorectal-pulmonary-metastases-single-centre-experience
#20
Craig D Ferguson, Chris R Luis, Karin Steinke
INTRODUCTION: To evaluate the safety and therapeutic efficacy of percutaneous microwave ablation (MWA) for colorectal pulmonary metastases. METHODS: Retrospective review of CT-guided lung MWA at a single tertiary institution. Adverse events within 30 days of MWA were considered procedure-related complications. Imaging follow-up was with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT and contrast-enhanced CT. Response of index tumours was assessed using modified response evaluation criteria in solid tumours (mRECIST)...
March 7, 2017: Journal of Medical Imaging and Radiation Oncology
keyword
keyword
65559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"